• Johnson & Johnson reported positive topline Phase 3 results for Caplyta in acute manic episodes tied to bipolar I disorder.
• Findings were already presented in a late-breaking session at the 2026 Psych Congress Annual Meeting.
• The trial showed rapid, sustained symptom improvement versus placebo, supporting a potential expansion beyond bipolar depression and schizophrenia.
• Caplyta is not approved for bipolar I mania; a second pivotal Phase 3 study has finished with analysis underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609210800PR_NEWS_USPR_____CG51607) on September 21, 2026, and is solely responsible for the information contained therein.